Diagnos (Diagnos) ROCE % : -2,783.33% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Diagnos ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Diagnos's annualized ROCE % for the quarter that ended in Dec. 2023 was -2,783.33%.

Diagnos ROCE % Historical Data

The historical data trend for Diagnos's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diagnos ROCE % Chart

Diagnos Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-1,161.07

-130.44

-222.87

-416.30

Diagnos Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-600.00	-796.50	-833.26	-734.56	-2,783.33

Diagnos ROCE % Calculation

Diagnos's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-1.609	/	( ( (1.218 - 0.521)	+	(0.601 - 0.525) )	/ 2 )
	=	-1.609	/	( (0.697	+	0.076)	/ 2 )
	=	-1.609	/	0.3865
	=	-416.30 %

Diagnos's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-2.004	/	( ( (0.706 - 0.598)	+	(0.625 - 0.589) )	/ 2 )
	=	-2.004	/	( ( 0.108	+	0.036 )	/ 2 )
	=	-2.004	/	0.072
	=	-2,783.33 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Diagnos (OTCPK:DGNOF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Diagnos ROCE % Related Terms

Thank you for viewing the detailed overview of Diagnos's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Diagnos (Diagnos) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diagnos Inc (OTCPK:DGNOF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ADK:Canada

Address

7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7

Website

http://www.diagnos.ca

Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in the business segment of Healthcare services. The company has a business presence in Canada, the United States, UAE, Saudi Arabia, Mexico, Costa Rica, and others. The company's key revenue is derived from Canada.